ANTI-RH(D) FOR THE TREATMENT OF HEPATITIS C ASSOCIATED IMMUNE THROMBOCYTOPENIA

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的主要目的是评估抗rh (D)治疗在丙型肝炎相关血小板减少症（血小板异常低的一种情况）中提高血小板计数的有效性和安全性。预计如果在该患者组中发现抗rh (D)的益处，将进行一项更大的前瞻性随机试验，将抗rh (D)与其他常用治疗方式（如皮质类固醇或IVIg）进行比较。由于目前的治疗方式存在问题，并且在这些患者中缺乏真正的护理标准，前瞻性随机研究等待确定其他有效且耐受性良好的治疗方法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aims of this study are to assess the effectiveness and safety of Anti-RH (D) therapy in elevating platelet counts in Hepatitis C associated thrombocytopenia (a condition when platelets are abnormally low). It is anticipated that if a benefit is seen with Anti-Rh (D) in this patient group, a larger prospective randomized trial will be conducted to compare Anti-Rh (D) to other commonly used treatment modalities, such as corticosteroids or IVIg. Because of the problems with current treatment modalities and the lack of a true standard of care in these patients, prospective randomized studies await the determination of additional effective and well-tolerated therapies.